secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001193125-25-326778
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics receives FDA approval for MYQORZO (aficamten) to treat symptomatic oHCM
--------------------------------------------------------------------------------

- FDA approved MYQORZO (aficamten) on Dec 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity, reducing contractility and LVOT obstruction.
- Available in 5 mg, 10 mg, 15 mg, and 20 mg tablets.
- Approval based on data showing improved functional capacity and symptoms in oHCM patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525326778/0001193125-25-326778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525326778/cytk-20251219.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-326778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer